MedTrace Logo

The Use of ARA290 for the Treatment of Diabetic Macular Oedema

NCT06626971 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2024-10-04

No results posted yet for this study

Summary

ARA 290-DMO is a prospective, open label, interventional, single centre, investigator led, phase II trial to examine the effect of ARA 290 on diabetic macular oedema in patients with type 1 or 2 diabetes.

The aim or primary objective of the study was to determine whether ARA 290 administered at a daily dose of 4mg subcutaneously for 12 weeks to patients with diabetes mellitus (DM) and DMO would have a beneficial effect on mean change in best corrected visual acuity (BCVA) from baseline values to week 12.

Conditions

  • Diabetic Macular Oedema

Interventions

DRUG

ARA290

4 mg subcutaneous injections of ARA290 over an 84 day period

Sponsors & Collaborators

  • Araim Pharmaceuticals, Inc.

    collaborator INDUSTRY

  • Belfast Health and Social Care Trust

    lead OTHER

Principal Investigators

  • Noemi Lois · Belfast Health & Social Care Trust and Queen's University Belfast

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2017-05-12
Completion
2017-08-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06626971 on ClinicalTrials.gov